Literature DB >> 26841827

Parkinson's disease: towards better preclinical models and personalized treatments.

Dan Lindholm1,2, Johanna Mäkelä3,4, Valentina Di Liberto5, Giuseppa Mudò5, Natale Belluardo5, Ove Eriksson3, Mart Saarma6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26841827     DOI： 10.1007/s00018-016-2141-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN： 1420-682X            Impact factor:   9.261


× No keyword cloud information.
  10 in total

1.  The need of a new and more physiological preclinical model for Parkinson's disease.

Authors:  Juan Segura-Aguilar; Irmgard Paris; Patricia Muñoz
Journal:  Cell Mol Life Sci       Date:  2016-01-23       Impact factor: 9.261

2.  Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons.

Authors:  Mats I Ekstrand; Mügen Terzioglu; Dagmar Galter; Shunwei Zhu; Christoph Hofstetter; Eva Lindqvist; Sebastian Thams; Anita Bergstrand; Fredrik Sterky Hansson; Aleksandra Trifunovic; Barry Hoffer; Staffan Cullheim; Abdul H Mohammed; Lars Olson; Nils-Göran Larsson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

3.  Parkinson's disease: 10 years of progress, 1997-2007.

Authors:  Stanley Fahn
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

Review 4.  Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy.

Authors:  Andrii Domanskyi; Mart Saarma; Mikko Airavaara
Journal:  Hum Gene Ther       Date:  2015-08       Impact factor: 5.695

Review 5.  GDNF family receptor complexes are emerging drug targets.

Authors:  Maxim M Bespalov; Mart Saarma
Journal:  Trends Pharmacol Sci       Date:  2007-01-10       Impact factor: 14.819

Review 6.  Repairing the parkinsonian brain with neurotrophic factors.

Authors:  Liviu Aron; Rüdiger Klein
Journal:  Trends Neurosci       Date:  2010-12-07       Impact factor: 13.837

Review 7.  Disease-modifying strategies for Parkinson's disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Anthony E Lang
Journal:  Mov Disord       Date:  2015-07-24       Impact factor: 10.338

8.  Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein.

Authors:  Eduard Bentea; Anke Van der Perren; Joeri Van Liefferinge; Anissa El Arfani; Giulia Albertini; Thomas Demuyser; Ellen Merckx; Yvette Michotte; Ilse Smolders; Veerle Baekelandt; Ann Massie
Journal:  Front Behav Neurosci       Date:  2015-03-31       Impact factor: 3.558

9.  GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System Function.

Authors:  Anmol Kumar; Jaakko Kopra; Kärt Varendi; Lauriina L Porokuokka; Anne Panhelainen; Satu Kuure; Pepin Marshall; Nina Karalija; Mari-Anne Härma; Carolina Vilenius; Kersti Lilleväli; Triin Tekko; Jelena Mijatovic; Nita Pulkkinen; Madis Jakobson; Maili Jakobson; Roxana Ola; Erik Palm; Maria Lindahl; Ingrid Strömberg; Vootele Võikar; T Petteri Piepponen; Mart Saarma; Jaan-Olle Andressoo
Journal:  PLoS Genet       Date:  2015-12-17       Impact factor: 5.917

10.  Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model.

Authors:  Stephanie Janezic; Sarah Threlfell; Paul D Dodson; Megan J Dowie; Tonya N Taylor; Dawid Potgieter; Laura Parkkinen; Steven L Senior; Sabina Anwar; Brent Ryan; Thierry Deltheil; Polina Kosillo; Milena Cioroch; Katharina Wagner; Olaf Ansorge; David M Bannerman; J Paul Bolam; Peter J Magill; Stephanie J Cragg; Richard Wade-Martins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205
  10 in total
  1 in total

1.  ATP Maintenance via Two Types of ATP Regulators Mitigates Pathological Phenotypes in Mouse Models of Parkinson's Disease.

Authors:  Masaki Nakano; Hiromi Imamura; Norio Sasaoka; Masamichi Yamamoto; Norihito Uemura; Toshiyuki Shudo; Tomohiro Fuchigami; Ryosuke Takahashi; Akira Kakizuka
Journal:  EBioMedicine       Date:  2017-07-25       Impact factor: 8.143
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.